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Less than 1% of CD19 and CD11b donor splenocytes origi-
nated from OP9-DL1 T-cell precursors. In our preliminary exper-
iments we did so far not observe any signs of graft-versus-host
disease (GVHD) in recipients of OP9-DL1 T-cell precursors. The
proliferative capacity of splenic T cells as determined by third-
party MLR was intact compared to controls. We conclude that the
co-culture of HSC with OP9-DL1 cells and growth factors results
in a 850- to 5000-fold expansion of  95% pure T-cell precursors,
which can home to the thymus after infusion into allo HSCT
recipients. These precursors undergo normal T-cell development,
reconstitute the periphery, proliferate to third party antigens, do
not cause GVHD, and improve donor T-cell chimerism. There-
fore, adoptive transfer of OP9-DL1 derived T-cell precursors
could signiﬁcantly enhance posttransplant T-cell reconstitution
without GVHD.
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PHASE I STUDY OF A NEUTRALIZING MONOCLONAL ANTI-CTLA4 AN-
TIBODY (MDX-010) IN PATIENTS WITH RELAPSE OF MALIGNANCY
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bashey, A.1; Medina, B.1; Zhong, R.-K.1; Zhou, J.-H.1; Carrier, E.1;
Castro, J.1; Holman, P.1; Lane, T.A.1; Sun, C.1; Lowy, I.2; Cor-
ringham, S.1; Soiffer, R.4; Mason, J.3; Ball, E.D.1 1. Division of Blood
and Marrow Transplantation, Moores Cancer Center, University of
California San Diego, La Jolla, CA; 2. Medarex, Inc., Bloomsbury, NJ;
3. Scripps Clinic, La Jolla, CA; 4. Dana Faber Cancer Institute, Boston,
MA.
Relapse of malignancy remains a major cause of treatment failure
after allogeneic hematopoietic stem cell transplantation (allo-
HCT). Tumors may utilize a variety of mechanisms to evade the
adoptive immunotherapy provided by allo-HCT. These may in-
clude lack of costimulation and direct or indirect inhibition of
T-cell activation. CTLA-4 (cytotoxic T-lymphocyte-associated
antigen-4) is a homologue of CD28 that functions as a negative
regulator of T-cell activation. Blockade of CTLA-4 using neutral-
izing antibodies has demonstrated potent anticancer effects in
animal models of antitumor immunity. Tumor regression as well as
autoimmune phenomena have been seen in phase I/II clinical trials
of CTLA-4 blockade in advanced solid tumors. Although CTLA-4
blockade may augment graft-versus-malignancy after allo-HCT,
GVHD and other immune complications may also be increased.
We have conducted a phase I dose-escalation trial of a neutralizing
human monoclonal anti-CTLA-4 antibody (MDX-010) in patients
with relapse of malignancy after allo-HCT. Eligibility criteria
included allo-HCT  90 days previously,  50% donor T-cell
chimerism, no prior grade 3/4 GVHD, and no prophylaxis/therapy
for GVHD for  6 weeks. Eligible patients received a single dose
of MDX-010 over 90 minutes. Patients were allowed DLI at a dose
of 5  106 CD3 cells/kg 8 weeks after MDX-010 if no GVHD
occurred and progression of malignancy (PD) was present. Six
patients (3 males and 3 females; median age 44 years; 2 cases of
CML, 1 case of AML, 1 case of myeloma, 1 case of renal carci-
noma, 1 case of breast cancer) have been treated (4 at a dose level
of 0.1 mg/kg, 3 at a dose level of 0.33 mg/kg). MDX-010 was well
tolerated in this setting; no infusional toxicity was seen. No patient
has developed clinically signiﬁcant exacerbation of GVHD or new-
onset GVHD after infusion. One patient (dose, 0.1 mg/kg) devel-
oped a grade 3 polyarthropathy with rheumatoid nodules 14 weeks
after MDX-010 and 6 weeks post-DLI, which resolved with cor-
ticosteroid therapy. No other autoimmune complications were
seen. MTD has not been reached. Two patients have demonstrated
possible anticancer responses (ie, partial remission of AML refrac-
tory to prior therapies, molecular remission of CML maintained
off imatinib). With a median follow-up of 164 days, 1 patient has
died (PD), 5 patients are alive, and 1 patient is in CR. Pharmaco-
kinetic and correlative science data will be presented. This study
shows safety with possible antitumor effects at the dose levels
tested.
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A PILOT STUDY EVALUATING THE SAFETY AND EFFICACY OF AMD3100
FOR THE MOBILIZATION AND TRANSPLANTATION OF HLA-MATCHED
SIBLING DONOR HEMATOPOIETIC STEM CELLS IN PATIENTS WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Andritsos, L.A.1; Edwards, T.1; Sempek, D.1; Calandra, G.2; Badel,
K.2; Vij, R.1; DiPersio, J.F.1; Devine, S.M.1 1. Washington University
School of Medicine, St Louis, MO; 2. Anormed Inc., Langley, BC,
Canada.
Cytokine-mobilized peripheral blood (MPB) has become the
preferred allograft source for patients with advanced hematological
malignancies. Procurement of MPB currently requires from 5 to 6
days of granulocyte colony-stimulating factor (G-CSF) adminis-
tration and is associated with donor morbidity and high cost.
Recent studies suggest G-CSF induces mobilization by indirectly
targeting the interaction between the chemokine stromal derived
factor 1 (SDF-1) and its receptor CXCR-4. Here we report pre-
liminary results using a direct antagonist of the SDF-1/CXCR-4
interaction, AMD3100, as a single agent to procure MPB from
allogeneic donors in only 1 or 2 days. Four HLA-identical siblings,
all males ranging from 40 to 58 years old, received 1 or 2 doses of
AMD3100 at 240 g/kg, followed 4 hours later by leukapheresis
(LP). After collection and a 1-week washout period, the same
donors were remobilized using G-CSF at 10 g/kg/day, followed
by LP commencing on day 5. The target CD34 cell dose fol-
lowing each agent was  2.0  106/kg recipient weight. The
results of the mobilizations and allograft composition are presented
in the table. After AMD3100, all donors tolerated treatment well,
and none experienced greater than grade 1 toxicity. All donors
experienced grade 2 bone pain during G-CSF mobilization. The
AMD3100-mobilized cells from 2 donors (donors 1 and 4) were
transplanted into a 51-year-old woman with AML and into a
48-year-old woman with NHL, respectively, after conditioning
with cyclophosphamide (120 mg/kg) and total body irradiation
(single 550-cGy dose). Both recipients engrafted neutrophils 
500/l promptly on days 10 and 11 and platelets  20,000/l
on days 14 and 20. Both patients are currently being fol-
lowed as outpatients and are without GVHD. The patient with
AML has full donor chimerism and normal trilineage hematopoi-
esis over 4 months following transplant and is in complete remis-
sion. The allografts collected from 2 donors were not given due to
progressive disease in the intended recipients. Grafts mobilized
after AMD3100 differ from G-CSF-mobilized allografts in the
content of CD34 and immune effector cells but appear to recon-
stitute hematopoiesis similarly. These preliminary data suggest
that a chemokine antagonist can safely and rapidly induce the
mobilization of a functionally competent hematopoietic allograft.
Accrual is ongoing, and additional donor/recipient pairs will be
presented.
Results of Mobilization
Agent AMD3100 AMD3100 AMD3100 AMD3100 AMD3100 G-CSF
Donor # 1 2 3 4 Combined
4
Combined
Median
Values
Median
Values
Days of drug
administration 2 1 2 2 2 5
# LP Procedures 2 1 2 2 2 1
Peak fold 1
CD34 7 6 7 5 6.5 22
CD34 dose
(106/kg) 2.6 2.1 1.2 2.5 2.3 2.9
CD3 dose
(108/kg) 4.9 1.5 2.7 3.2 3.8 1.3
CD4 dose
(108/kg) 3.1 1.0 2.0 3.2 2.5 0.8
CD8 dose
(108/kg) 1.7 0.4 0.6 3.4 1.2 0.5
CD56 dose
(107/kg) 3.4 2.1 2.7 3.7 3.1 1.9
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